Literature DB >> 7699228

Risk factors in primary sclerosing cholangitis.

E Schrumpf1, M Abdelnoor, O Fausa, K Elgjo, E Jenssen, F Kolmannskog.   

Abstract

The increasing use of liver transplantation and new treatment regimens requires an accurate estimate of the prognosis in primary sclerosing cholangitis. To clarify the natural history and prognosis of this disease, we studied the clinical features at the time of presentation and the outcome in 77 consecutive patients admitted to our hospital. The median age at diagnosis of primary sclerosing cholangitis was 32.5 years; 66% of the patients were male; 76 had concomitant inflammatory bowel disease and two had celiac disease. Thirty-four patients were classified as asymptomatic at diagnosis of primary sclerosing cholangitis. The mean follow-up time was 6.2 years; 25 patients have died or been transplanted. Cholangiocarcinoma has been diagnosed in 11 patients (14%). Female patients have a significantly poorer survival rate than male patients. The bilirubin level was found to be an independent risk factor for both mortality/transplantation, and for the occurrence of cholangiocarcinoma. Age at diagnosis of primary sclerosing cholangitis was an additional risk factor of death/transplantation. As bilirubin is an important prognostic factor for the development of both cholangiocarcinoma and death/transplantation, the construction of prognostic indices seems to be of limited value in the timing of transplantation of the individual patient.

Entities:  

Mesh:

Year:  1994        PMID: 7699228     DOI: 10.1016/s0168-8278(05)80618-x

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  23 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era.

Authors:  David Goldberg; Benjamin French; Arwin Thomasson; K Rajender Reddy; Scott D Halpern
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

Review 3.  Genetic epidemiology of primary sclerosing cholangitis.

Authors:  Tom-H Karlsen; Erik Schrumpf; Kirsten-Muri Boberg
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

Review 4.  Primary sclerosing cholangitis--approach to diagnosis.

Authors:  Ian L Steele; Cynthia Levy; Keith D Lindor
Journal:  MedGenMed       Date:  2007-04-25

Review 5.  Controversies in the management of primary sclerosing cholangitis.

Authors:  Jeremy S Nayagam; Stephen P Pereira; John Devlin; Phillip M Harrison; Deepak Joshi
Journal:  World J Hepatol       Date:  2016-02-18

Review 6.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

7.  Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study.

Authors:  S A Mitchell; M Thyssen; T R Orchard; D P Jewell; K A Fleming; R W Chapman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  Primary sclerosing cholangitis treated by endoscopic biliary dilation: review and long-term follow-up evaluation.

Authors:  G Kenneth Johnson; Kia Saeian; Joseph E Geenen
Journal:  Curr Gastroenterol Rep       Date:  2006-04

9.  Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma.

Authors:  Monika Forsbring; Erik S Vik; Bjørn Dalhus; Tom H Karlsen; Annika Bergquist; Erik Schrumpf; Magnar Bjørås; Kirsten M Boberg; Ingrun Alseth
Journal:  Carcinogenesis       Date:  2009-05-14       Impact factor: 4.944

Review 10.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.